Back to Search
Start Over
Overview of recent advances in metastatic triple negative breast cancer
- Source :
- World Journal of Clinical Oncology
- Publication Year :
- 2021
- Publisher :
- Baishideng Publishing Group Inc, 2021.
-
Abstract
- Metastatic triple negative breast cancer (TNBC) has an aggressive phenotype with a predilection for visceral organs and brain. Best responses to chemotherapy are predominately in the first line. Recent studies have demonstrated improved progression free survival with the combination of atezolizumab/pembrolizumab and chemotherapy in programmed death-ligand 1 positive metastatic TNBC. However, a recent trial in a similar population showed no benefit for atezoli-zumab and paclitaxel which led to a Food and Drug Administration alert. Two phase III trials (OLYMPIAD and BROCADE3) demonstrated a benefit in progression free survival (PFS) but not overall survival in patients with BRCA-associated metastatic TNBC treated with Olaparib or Talazoparib respectively. For those treated with Talazoparib, the time to deterioration in health related-quality of life was also longer compared to chemotherapy. The BROCADE3 trial demonstrated that the combination of a platinum and veliparib increased PFS in first-line metastatic TNBC but at the cost of increased toxicity. There are no head-to-head comparisons of a poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) and platinums. There are unanswered questions regarding the role of PARPi maintenance after platinum therapy as is standard of care in BRCA-associated ovarian cancer. Other areas of therapeutic interest include targeting aberrations in the phosphoinositide 3-kinase pathway, protein kinase B, mammalian target of rapamycin or utilising antibody drug conjugates. This review focusses on recent and emerging therapeutic options in metastatic TNBC. We searched PubMed, clinicaltrials.gov and recent international meetings from American Society of Clinical Oncology, San Antonio Breast Cancer Conference and the European Society of Medical Oncology.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Veliparib
Population
Pembrolizumab
Olaparib
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
Atezolizumab
Internal medicine
medicine
Triple negative breast cancer
Progression-free survival
education
Triple-negative breast cancer
education.field_of_study
business.industry
Poly (adenosine diphosphate-ribose) polymerase inhibitors
Minireviews
medicine.disease
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Immunotherapy
business
Subjects
Details
- Language :
- English
- ISSN :
- 22184333
- Volume :
- 12
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- World Journal of Clinical Oncology
- Accession number :
- edsair.doi.dedup.....f8ff47c613e2e97e9360085013c6d3f1